147 related articles for article (PubMed ID: 38739593)
1. CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.
Azur RAG; Olarte KCV; Ybañez WS; Ocampo AMM; Bagamasbad PD
PLoS One; 2024; 19(5):e0300413. PubMed ID: 38739593
[TBL] [Abstract][Full Text] [Related]
2. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
5.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
7. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
8. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
[TBL] [Abstract][Full Text] [Related]
9. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.
Fraser JA; Sutton JE; Tazayoni S; Bruce I; Poole AV
Sci Rep; 2019 Dec; 9(1):19076. PubMed ID: 31836808
[TBL] [Abstract][Full Text] [Related]
10. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.
Terry S; Maillé P; Baaddi H; Kheuang L; Soyeux P; Nicolaiew N; Ceraline J; Firlej V; Beltran H; Allory Y; de la Taille A; Vacherot F
Neoplasia; 2013 Jul; 15(7):761-72. PubMed ID: 23814488
[TBL] [Abstract][Full Text] [Related]
11. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
12. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
[TBL] [Abstract][Full Text] [Related]
13. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
14. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival.
Vlachostergios PJ; Karathanasis A; Tzortzis V
Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052475
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
17. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
18. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
19. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
